Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03377179 · ClinicalTrials.gov registry record · Phase 2
A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma
A Phase 2 study of Cholangiocarcinoma and Cholangiocarcinoma, Intrahepatic, sponsored by RedHill Biopharma Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
- 5
- Study locations
NCT03377179 is a Phase 2 study of Cholangiocarcinoma and Cholangiocarcinoma, Intrahepatic that has completed, run by RedHill Biopharma Limited. The registered enrollment target is 65 participants, below the 385-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target (83% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT03377179, a Phase 2 study of Cholangiocarcinoma and Cholangiocarcinoma, Intrahepatic, has completed, sponsored by RedHill Biopharma Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
- 5
- Study locations
Study Summary
ABC-108 is a single-arm Phase IIA clinical study of ABC294640 (Yeliva ®, opaganib) alone and in combination with hydroxychloroquine sulfate (HCQ) in the treatment of cholangiocarcinoma (CCA). In Part 1 of this clinical study, all participants will be receiving ABC294640 and in Part 2 all participants will be receiving ABC294640 and HCQ to explore the drugs activity signal in CCA. The study drug, ABC294640 is an orally available inhibitor of the enzyme sphingosine kinase-2 (SK2). SK2 is an innovative target for anti-cancer therapy because of its critical role in sphingolipid metabolism, which is known to regulate tumor cell death and proliferation. ABC294640 also inhibits proliferation and induces apoptosis of cholangiocarcinoma cell lines. Furthermore, in a recent Phase I trial, ABC294640 demonstrated clinical activity in CCA patients. HCQ, is an orally available, FDA approved therapy for the treatment of malaria as well as discoid and systemic lupus erythematosus and rheumatoid arthritis. It is also known as an inhibitor of autophagy, a pro-survival mechanism utilized by many cancers. Evidence indicates that inhibition of autophagy can increase the therapeutic activity of ABC294640 in CCA. In Part 1 of this study, ABC294640 will be continuously administrated orally, twice a day, in 28 day cycles. In Part 2, ABC294640 and HCQ will be continuously administrated orally (the safe and tolerable will be determined in the study) in 28 day cycles. Administration of drug/s in both parts of the study will continue until disease progression, unacceptable toxicity or voluntary withdrawal initiated by the participants or physician.
Conditions Studied
Interventions
- DRUG ABC294640
- DRUG Hydroxychloroquine Sulfate 200 MG
Study Locations (5)
Arizona
- Mayo Clinic Cancer Center - Phoenix
Georgia
- Emory University - Atlanta
Minnesota
- Mayo Clinic Cancer Center - Rochester
Texas
- MD Anderson Cancer Center - Houston
Utah
- Huntsman Cancer Institute, University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2018-03-07 |
| Est. Completion | 2022-06-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03377179
The ClinicalTrials.gov registry entry for NCT03377179 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 385-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target (83% lower). The listed sponsor is RedHill Biopharma Limited, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Cholangiocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which ABC294640 is the first listed.
NCT03377179 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Arizona, Georgia, Minnesota.
Frequently Asked Questions
What is clinical trial NCT03377179 about?
NCT03377179 is a clinical study titled "A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma". ABC-108 is a single-arm Phase IIA clinical study of ABC294640 (Yeliva ®, opaganib) alone and in combination with hydroxychloroquine sulfate (HCQ) in the treatment of cholangiocarcinoma (CCA). In Part 1 of this clinical study, all participants will be receiving ABC294640 and in Part 2 all participant...
What is the current status of trial NCT03377179?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2018-03-07. Estimated completion is 2022-06-21.
What conditions does trial NCT03377179 study?
This clinical trial studies the following conditions: Cholangiocarcinoma, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Perihilar, Cholangiocarcinoma, Extrahepatic.
What interventions are being tested in trial NCT03377179?
The interventions under investigation include: ABC294640 (DRUG), Hydroxychloroquine Sulfate 200 MG (DRUG).
Who is sponsoring clinical trial NCT03377179?
This trial is sponsored by RedHill Biopharma Limited, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03377179 being conducted?
This trial has 5 study locations across Arizona, Georgia, Minnesota, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cholangiocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
RECRUITING · Phase 2
-
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
RECRUITING · Phase 2
-
A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma
RECRUITING · Phase 2
-
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
RECRUITING · Phase 2
-
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.